Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Kura Oncology Inc's Business Segments
Kura Oncology Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
5
Largest Segment
License and Collaboration Revenue
Total Revenue
$ 21
Regions Reported
-
Revenue Share by Reportable Segment - FY
- License and Collaboration Revenue0%
- Member0%
- Product71.3%
- Development Services for Monotherapy64.2%
- Development Services in Combination With Other Therapies52.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License and Collaboration Revenue | $ 24 | - |
| Member | $ 24 | - |
| Product | $ 15 | 71.3% |
2 more segments available
Sign in to unlock the full Kura Oncology Inc dataset.
Revenue by Product & Service Category - FY
- License and Collaboration Revenue68.4%
- Collaboration Revenue68.4%
- Product31.6%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License and Collaboration Revenue | $ 12 | 68.4% |
| Collaboration Revenue | $ 12 | 68.4% |
| Product | $ 6 | 31.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- License and Collaboration Revenue0%
- Member0%
- Product71.3%
- Development Services for Monotherapy64.2%
- Development Services in Combination With Other Therapies52.2%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| License and Collaboration Revenue | $ 24 | - |
| Member | $ 24 | - |
| Product | $ 15 | 71.3% |
2 more segments available
Sign in to unlock the full Kura Oncology Inc dataset.
Description of Kura Oncology Inc
Kura Oncology Inc is a publicly-traded biopharmaceutical company headquartered in La Jolla, California. The company is focused on developing innovative medicines for the treatment of cancer. Kura’s lead drug candidate, tipifarnib, is a selective farnesyltransferase inhibitor, which inhibits a critical enzyme in the Ras pathway, and has shown promising results in various clinical trials.
The company was founded in 2014 by Troy Wilson and Yi Liu. It raised $60 million in its initial public offering in 2015, and since then has continued to raise additional capital through secondary offerings and collaborations. As of 2021, Kura has a market capitalization of over $1 billion.
Kura is focused on developing drugs that target various cancer indications, particularly those with high unmet medical needs. The company’s pipeline includes several promising drug candidates in various stages of development, including KRA inhibitor, Kura-009, which is in Phase I clinical trials for the treatment of solid tumors with K-Ras mutations, and Menin-MLL inhibitor, KO-539, which is in preclinical development for the treatment of patients with leukemias and several other hematologic malignancies.
The company’s lead drug candidate, tipifarnib, has the potential to be a game-changer in the treatment of hematologic malignancies, particularly in acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). Tipifarnib has already been granted fast track designation by the FDA, and its ongoing phase II clinical trials are showing promising results. The drug has also shown potential in treating other indications such as advanced head and neck cancer and peripheral T-cell lymphoma.
Kura’s scientific team consists of experts in drug discovery, preclinical evaluation, clinical development, and regulatory affairs. The company has a collaborative approach and works closely with academic institutions, clinical investigators, and industry partners, making it a leading player in the field of oncology drug development.
In summary, Kura Oncology Inc is a fast-growing biopharmaceutical company that is committed to developing innovative drugs for the treatment of cancer, particularly hematologic malignancies. The company’s pipeline of drug candidates, led by the promising tipifarnib, has the potential to revolutionize cancer treatment and improve the lives of patients suffering from cancer.
The company was founded in 2014 by Troy Wilson and Yi Liu. It raised $60 million in its initial public offering in 2015, and since then has continued to raise additional capital through secondary offerings and collaborations. As of 2021, Kura has a market capitalization of over $1 billion.
Kura is focused on developing drugs that target various cancer indications, particularly those with high unmet medical needs. The company’s pipeline includes several promising drug candidates in various stages of development, including KRA inhibitor, Kura-009, which is in Phase I clinical trials for the treatment of solid tumors with K-Ras mutations, and Menin-MLL inhibitor, KO-539, which is in preclinical development for the treatment of patients with leukemias and several other hematologic malignancies.
The company’s lead drug candidate, tipifarnib, has the potential to be a game-changer in the treatment of hematologic malignancies, particularly in acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). Tipifarnib has already been granted fast track designation by the FDA, and its ongoing phase II clinical trials are showing promising results. The drug has also shown potential in treating other indications such as advanced head and neck cancer and peripheral T-cell lymphoma.
Kura’s scientific team consists of experts in drug discovery, preclinical evaluation, clinical development, and regulatory affairs. The company has a collaborative approach and works closely with academic institutions, clinical investigators, and industry partners, making it a leading player in the field of oncology drug development.
In summary, Kura Oncology Inc is a fast-growing biopharmaceutical company that is committed to developing innovative drugs for the treatment of cancer, particularly hematologic malignancies. The company’s pipeline of drug candidates, led by the promising tipifarnib, has the potential to revolutionize cancer treatment and improve the lives of patients suffering from cancer.
Kura Oncology Inc is a clinical-stage biopharmaceutical company that specializes in developing innovative therapies for cancer treatment. The company is dedicated to advancing precision oncology therapeutics, focusing on identifying and targeting specific genetic and biomarker-defined cancer subtypes. Below is an extensive overview of the segments, products, and services offered by Kura Oncology Inc.
Segments
1. Precision Oncology Therapeutics:
This segment is the cornerstone of Kuras operations and is dedicated to the development of therapeutic candidates targeting genetically defined cancers. By leveraging advanced genetic testing and genomic profiling, this segment seeks to create treatments that are not only effective but also tailored to the individual genetic profiles of patients’ tumors. It represents a paradigm shift in oncology that prioritizes personalized medicine, enhancing the potential for successful treatment outcomes.
2. Biomarker-Based Cancer Super Types:
Within this segment, the company focuses on the study of cancer super types that share common genetic characteristics. By understanding the biological mechanisms that underlie these super types, Kura Oncology aims to develop therapies that can effectively target broader classes of cancer. This approach allows for a more comprehensive understanding of cancer biology and aids in the identification of new therapeutic targets and biomarkers for diagnosis and treatment efficacy.
Products
1. Tipifarnib:
Tipifarnib is Kura Oncology’s lead product candidate, designed for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC). This investigational drug has demonstrated significant inhibitory effects on HRAS mutant tumors in clinical studies, showcasing its potential as a targeted therapy. The emphasis on HRAS mutations highlights Kuras strategy to develop therapies that address specific genetic alterations leading to cancer, thereby improving patient outcomes.
2. KO-947:
KO-947 is a small molecule therapeutic candidate that is being explored for the treatment of acute myeloid leukemia (AML) and other hematological malignancies. It has exhibited potent in vitro activity against a variety of hematological cancer cell lines. KO-947 represents Kuras ongoing efforts to develop treatments that disrupt the signaling pathways crucial for the survival and proliferation of cancer cells, aligning with the company’s focus on precision oncology.
Services
1. Clinical Trial Development:
Kura Oncology possesses a dedicated clinical trial development team responsible for the design, management, and execution of clinical trials for its product candidates. This includes strategic planning around trial design, patient recruitment, and compliance with regulatory requirements. The team focuses on optimizing trial protocols to ensure that the development processes are efficient, ethical, and aligned with the latest scientific findings.
2. Biomarker Discovery:
The biomarker discovery team at Kura Oncology conducts extensive research to identify and validate biomarkers, which are critical for patient selection and treatment stratification. Identifying the right biomarker can indicate which patients are more likely to respond to specific therapies, thus enhancing the effectiveness of treatments and reducing unnecessary exposures to therapies that may not benefit them.
3. Preclinical Drug Development:
This team is essential to Kuras pipeline, overseeing the identification and development of new drug candidates that target specific genetic and biomarker-defined cancer subtypes. Engaging in preclinical studies allows the company to gather essential data on drug efficacy, safety, and mechanism of action before advancing candidates into clinical trials.
Conclusion
Kura Oncology Inc is at the forefront of cancer therapeutics development, combining innovative drug discovery with precision medicine approaches. Through its segments focused on precision oncology therapeutics and biomarker-based cancer super types, along with key products like Tipifarnib and KO-947, the company seeks to transform the landscape of cancer treatment. Additionally, its comprehensive services in clinical trial development, biomarker discovery, and preclinical drug development underscore its commitment to advancing effective and personalized cancer therapies. These efforts reflect Kuras strategic goal of developing targeted treatments that can significantly improve the prognosis for cancer patients.
Segments
1. Precision Oncology Therapeutics:
This segment is the cornerstone of Kuras operations and is dedicated to the development of therapeutic candidates targeting genetically defined cancers. By leveraging advanced genetic testing and genomic profiling, this segment seeks to create treatments that are not only effective but also tailored to the individual genetic profiles of patients’ tumors. It represents a paradigm shift in oncology that prioritizes personalized medicine, enhancing the potential for successful treatment outcomes.
2. Biomarker-Based Cancer Super Types:
Within this segment, the company focuses on the study of cancer super types that share common genetic characteristics. By understanding the biological mechanisms that underlie these super types, Kura Oncology aims to develop therapies that can effectively target broader classes of cancer. This approach allows for a more comprehensive understanding of cancer biology and aids in the identification of new therapeutic targets and biomarkers for diagnosis and treatment efficacy.
Products
1. Tipifarnib:
Tipifarnib is Kura Oncology’s lead product candidate, designed for the treatment of patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC). This investigational drug has demonstrated significant inhibitory effects on HRAS mutant tumors in clinical studies, showcasing its potential as a targeted therapy. The emphasis on HRAS mutations highlights Kuras strategy to develop therapies that address specific genetic alterations leading to cancer, thereby improving patient outcomes.
2. KO-947:
KO-947 is a small molecule therapeutic candidate that is being explored for the treatment of acute myeloid leukemia (AML) and other hematological malignancies. It has exhibited potent in vitro activity against a variety of hematological cancer cell lines. KO-947 represents Kuras ongoing efforts to develop treatments that disrupt the signaling pathways crucial for the survival and proliferation of cancer cells, aligning with the company’s focus on precision oncology.
Services
1. Clinical Trial Development:
Kura Oncology possesses a dedicated clinical trial development team responsible for the design, management, and execution of clinical trials for its product candidates. This includes strategic planning around trial design, patient recruitment, and compliance with regulatory requirements. The team focuses on optimizing trial protocols to ensure that the development processes are efficient, ethical, and aligned with the latest scientific findings.
2. Biomarker Discovery:
The biomarker discovery team at Kura Oncology conducts extensive research to identify and validate biomarkers, which are critical for patient selection and treatment stratification. Identifying the right biomarker can indicate which patients are more likely to respond to specific therapies, thus enhancing the effectiveness of treatments and reducing unnecessary exposures to therapies that may not benefit them.
3. Preclinical Drug Development:
This team is essential to Kuras pipeline, overseeing the identification and development of new drug candidates that target specific genetic and biomarker-defined cancer subtypes. Engaging in preclinical studies allows the company to gather essential data on drug efficacy, safety, and mechanism of action before advancing candidates into clinical trials.
Conclusion
Kura Oncology Inc is at the forefront of cancer therapeutics development, combining innovative drug discovery with precision medicine approaches. Through its segments focused on precision oncology therapeutics and biomarker-based cancer super types, along with key products like Tipifarnib and KO-947, the company seeks to transform the landscape of cancer treatment. Additionally, its comprehensive services in clinical trial development, biomarker discovery, and preclinical drug development underscore its commitment to advancing effective and personalized cancer therapies. These efforts reflect Kuras strategic goal of developing targeted treatments that can significantly improve the prognosis for cancer patients.